Purpose/Objective: To investigate the impact of surgery, oncoplastic surgery versus lumpectomy, on the volume of tumor bed delineation in irradiated breast cancer (BC) patients. Materials and Methods: A consecutive series of 293 BC patients were treated with breast conserving surgery followed by radiotherapy. Of this series, 44 patients underwent an oncoplastic procedure and were included in this study. The control group consisted of 67 patients who underwent a lumpectomy. The controls were matched for location (lateral upper quadrant versus other) and tumor to breast ratio (small versus large). For the small tumor to breast ratio group we included 2 controls for each oncoplastic patient. For the group with large tumor to breast ratios we included all available patients (1 to 1). The tumor bed was delineated based on the presence of the surgical clips, hematoma, seroma and/or other surgery-induced changes and interpretation of radiology, pathology and surgical reports. The association between surgery (oncoplastic surgery versus lumpectomy) and delineated tumor bed volumes in cm 3 was assessed with linear regression analyses. Here we present the crude association (using univariable analysis) and the association corrected for confounding factors (using multivariable analysis). Only confounders that changed the association more than 10% were included. In these analyses the outcome delineated tumor bed volume was log-transformed, the estimated beta's represent the change in log tumor bed volume. Results: The oncoplastic operated patients had a radiological larger median tumor diameter (21 mm versus 14 mm) than the lumpectomy patients. The volume of the pathological specimen was not significantly different between the two groups: 148.8 cm 3 in the oncoplastic group and 135.0 cm 3 in the lumpectomy group. The median delineated tumor bed volume was significantly larger after oncoplastic surgery compared to lumpectomy alone (26.3 cm3 vs. 16.4 cm3, p<0.001). In the univariable analysis the delineated tumor bed volume was 1.7 (β = 0.547, 95% CI 0.297-0.797) times larger in patients with an oncoplastic procedure than in the patients who underwent a lumpectomy only. After correcting for confounders (presence of postoperative seroma and radiological tumor diameter (mm)) the delineated tumor bed volume after the oncoplastic procedure was 1.9 (β = 0.616, 95% CI 0.353-0.879) times larger than after a lumpectomy only. Conclusions: Oncoplastic surgery in breast conserving treatment for breast cancer results in larger tumor bed volumes for radiotherapy. 
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Implementation of a breath-hold lung gating system for left-sided breast cancer; hurdles and benefits R. Purpose/Objective: Left sided breast cancer poses a significant challenge in sparing the heart and specifically the left descending coronary vessels (LCV). Often, a compromise between PTV coverage and OAR sparing must be made. Lung Gating is seen as a useful method to maximize both. However, it is always associated with increased complexity, cost and time. We prospectively evaluated the cost-benefit of a modern system implemented in a busy community hospital environment. Materials and Methods: A lung gating system based on the breath-hold technique (SDX, QFix, Avondale PN, USA) was evaluated on a consecutive series of patients with left sided breast cancer. Breath hold training and the acquisition of an inspiratory (IN) and expiratory (EX) planning dataset were the basis for deciding which patients would be eligible for gated irradiation. After contouring of PTV, left lung, heart and LCV in the IN dataset, the structures were copied to the EX dataset and adapted nonrigidly. Treatment planning was performed in identical manner for both datasets (IMRT via mainly 2 tangential fields with up to 16 segments), allowing optimal comparison between IN-and EX plans. We also report the positioning deviations in the A-P direction derived from the weekly portal images. Results: Of the initial 26 consecutive patients, 25 could be CT-planned with the system resulting in 2 datasets each ( IN and EX). Of these, 14 (56%) were initially selected for treatment in inspiration due to a significant difference in one or more OAR. Lung gating had to be discontinued in two patients after 3 and 2 fractions respectively due to breathhold difficulties which had not been apparent during the training session. In patients initially selected for lung gating, the maximum (D02) and median (D50) doses to the LCV were 9.5(range 2.5-48.4) Gy and 3.1(1.8-25.1) Gy, respectively, and were significantly lower than those derived from the EX plans (p<0.001). The corresponding doses for the patients not selected for lung gating were 35.5 (7.3-57.2) Gy and 7.0 (3.1-39.7) Gy for D02 and D50, respectively, which was not significantly different from their IN plan values. Better LCV sparing in lung gated patients was not due to compromising PTV coverage: The volume of the PTV covered with 95% of prescribed dose was 90(73-97)% and 89(83-97)% for lung gated and non-lung gated patients, respectively (p=0.90).Median treatment times were 478±63s seconds for the lung-gated patients vs. 278±37s seconds for the patients treated without. The average A-P deviation (n=121) was 2.1 mm. Conclusions: These results represent the very first patients treated at our institution with this system. Lung-gating prolonged treatment time surprisingly little by approximately 3 minutes per fraction and offered significant benefits on OAR sparing to 50 % of the patients. Thorax-excursion reproducibility is highly accurate with this system. As a limitation, it is only suitable for patients who are able to understand both the spoken and visual commands and are fully compliant.
